Monitor future CMS announcements on Exogen reimbursement rates, as further changes could pressure revenue. The reiteration of guidance suggests near-term stability, but the long-term reimbursement trajectory remains uncertain.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 22 $9.28entry
- T+1 · 6mo ago −2.80%α −3.39% · $9.02
- T+5 · 6mo ago −14.55%α −16.21% · $7.93
- T+20 · 5mo ago −3.13%α −1.71% · $8.99
- T+60 · 3mo ago +54.09%α +50.90% · $14.30
Price Chart
How similar events traded
Executive Summary
Bioventus disclosed that the FDA reclassified its Exogen Ultrasound Bone Healing System from Class III to Class II, and CMS updated billing requirements and the Medicare fee schedule effective May 18, 2026. The company does not expect the reimbursement rate changes to have a material impact on 2026 financial results and is reiterating its prior guidance.
Key Facts
- FDA reclassified non-invasive bone growth stimulators (including Exogen) from Class III to Class II on April 16, 2026.
- CMS updated billing requirements and Medicare fee schedule for HCPCS codes E0747, E0748, E0760 effective May 18, 2026.
- Bioventus does not expect the reimbursement changes to materially impact FY2026 financial results.
- Company is reiterating previously issued 2026 financial guidance.
- Potential future CMS actions could require a revision of financial outlook.
Financial Impact
No material impact expected for FY2026; no specific dollar amounts provided.
Risk Factors
- Future CMS rate cuts could materially reduce Exogen revenue.
- Reclassification may invite competitive entry or additional regulatory requirements.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001665988-26-000029 |
| Document: 0001665988-26-000029-index-headers.html | 0001665988-26-000029 |
| Document: 0001665988-26-000029-index.html | 0001665988-26-000029 |
| Document: 0001665988-26-000029.txt | 0001665988-26-000029 |
Track record
18 reports on BVS
2 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +37.19% at T+60 after the May 8, 2026 report. 3 of 7 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $10.66 Now $10.46 −1.88% settles Feb 11
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $10.61 Now $10.46 −1.41% settles Feb 4
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $10.95 Now $10.46 −4.43% settles Feb 1
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $14.65 Now $10.46 −28.60% settles Jan 26
- Aug 15, 202613w ago Institutional Cluster Mixed 5/10 Entry $13.88 to $11.02 Now $10.46 −24.64% ▼ −20.64% −17.88% vs SPY
- Aug 5, 202614w ago 8-K Bullish 7/10 No price data
- Aug 5, 202614w ago Press Release Bullish 7/10 Entry $15.26 to $14.86 Now $10.46 −31.45% ▼ −2.62% −2.81% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 4/10 Entry $8.68 to $14.07 Now $10.46 −20.51% ▼ −62.10% −57.70% vs SPY
- Jun 2, 202623w ago Press Release Bearish 6/10 Entry $8.11 to $13.97 Now $10.46 −28.98% ▼ −72.26% −71.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers